- Home
- BBIO vs ALLY Comparison
BBIO vs ALLY Comparison
Compare BBIO & ALLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBIO | ALLY |
|---|---|---|
| Founded | 2015 | 1919 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 14.1B |
| IPO Year | 2019 | 2011 |
Fundamental Metrics
Financial Performance| Metric | BBIO | ALLY |
|---|---|---|
| Price | $70.20 | $37.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 24 | 16 |
| Target Price | ★ $83.00 | $49.87 |
| AVG Volume (30 Days) | 2.4M | ★ 3.3M |
| Earning Date | 05-22-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | N/A | ★ 31.67 |
| EPS | N/A | ★ 2.37 |
| Revenue | $502,076,000.00 | ★ $7,914,000,000.00 |
| Revenue This Year | $88.86 | $24.71 |
| Revenue Next Year | $74.11 | $6.19 |
| P/E Ratio | ★ N/A | $15.81 |
| Revenue Growth | ★ 126.26 | N/A |
| 52 Week Low | $28.33 | $29.52 |
| 52 Week High | $84.94 | $47.27 |
Technical Indicators
Market Signals| Indicator | BBIO | ALLY |
|---|---|---|
| Relative Strength Index (RSI) | 50.29 | 39.61 |
| Support Level | $61.95 | $37.38 |
| Resistance Level | $78.20 | $38.05 |
| Average True Range (ATR) | 2.75 | 1.34 |
| MACD | 0.64 | -0.12 |
| Stochastic Oscillator | 56.57 | 29.81 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About ALLY Ally Financial Inc.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.